Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Yanina Corrada x
  • Refine by Access: All Content x
Clear All Modify Search


Objective—To determine whether cabergoline would be safe and effective for induction of estrus in dogs with primary or secondary anestrus.

Design—Prospective case series.

Animals—6 privately owned otherwise healthy purebred dogs with primary or secondary anestrus.

Procedure—Dogs were treated with cabergoline (5 µg/kg [2.3 µg/lb], PO, q 24 h) until 2 days after the onset of proestrus. Follicular development was assessed by means of cytologic examination of vaginal smears; ovulation was assessed by measuring serum progesterone concentration 3 weeks after the onset of estrus. Five bitches were mated during behavioral estrus.

Results—All dogs had normal estrus periods, and all 5 dogs that were mated whelped normal litters. Mean duration of cabergoline treatment was 16 days. None of the dogs had any adverse effects associated with cabergoline administration.

Conclusions and Clinical Relevance—Results suggest that administration of cabergoline is safe and effective for treatment for primary and secondary anestrus in dogs. (J Am Vet Med Assoc 2002;220: 1653–1654)

Restricted access
in Journal of the American Veterinary Medical Association

An 11-month-old healthy male Miniature Poodle was referred because of infertility. The dog was the only male at the kennel, and no other animals at the kennel were infertile.

During the preceding 2 months, the dog had mated with 4 previously fertile bitches, none of which became pregnant. Libido and sexual behavior of the dog during those matings were considered normal. Each of the matings was followed by a corresponding copulatory tie. The medical history did not reveal husbandry problems, inbreeding, or administration of any drugs that would interfere with fertility of this particular dog or the other animals

Restricted access
in Journal of the American Veterinary Medical Association


Objective—To assess the efficacy and safety of 2 protocols using bromocriptine mesylate and prostaglandins to terminate unwanted pregnancy in bitches.

Design—Prospective randomized single-blind controlled study.

Animals—34 crossbred and purebred bitches referred for possible pregnancy termination. Seven additional pregnant bitches were used as controls.

Procedure—Pregnancy was assessed by ultrasonographic examination from day 25 after mating in all bitches. Of the 34 bitches, 25 were pregnant and were randomly allocated to a treatment group. Group- 1 dogs (n = 12) received a combination of increasing amounts of bromocriptine mesylate (15 to 30 µg/kg [6.8 to 13.6 µg/lb], PO, q 12 h) and dinoprost tromethamine (0.1 to 0.2 mg/kg [0.045 to 0.09 mg/lb], SC, q 24 h). Group-2 dogs (n =13) received a combination of increasing amounts of bromocriptine mesylate (the same schedule as group-1 dogs) and cloprostenol sodium (1 µg/kg [0.45 µg/lb], SC, q 48 h). Both groups were treated until pregnancy termination.

Results—Treatment success was 100% in both groups. Days of treatment required for pregnancy termination did not significantly differ between groups (5.0 ± 0.6 vs 3.7 ± 0.6 days, group-1 and group-2 dogs, respectively) although adverse effects only developed in group-1 dogs. At the end of the protocols, pseudopregnancy was observed in 3 of 12 and 6 of 13 group-1 and group-2 dogs, respectively. Pregnancy termination was followed by a mucoid sanguineous vulvar discharge for 3 to 10 days.

Conclusions and Clinical Relevance—Results of this study indicate that protocols that combine the use of bromocriptine mesylate and prostaglandins for the termination of unwanted pregnancy in bitches are efficient and safe. The use of bromocriptine mesylate and cloprostenol had the best results and could be easily used on an outpatient basis. (J Am Vet Med Assoc 2002;220:1017–1019)

Restricted access
in Journal of the American Veterinary Medical Association